Retatrutide and Hair Loss: What the Evidence Shows

For retatrutide specifically, this review did not identify a reliable trial-based hair-loss rate. Its weight-loss results cannot be used to predict that it will cause the most shedding or to assign it tirzepatide’s alopecia rate.

How Weight Loss Causes Hair Loss

The hair growth cycle

Hair follicles cycle through growth (anagen), transition (catagen) and rest (telogen). Shedding and regrowth do not respond instantly to a change in weight or medication.

What is telogen effluvium?

Telogen effluvium is increased shedding that can follow a physical stressor such as substantial weight loss, illness, surgery or childbirth. It often becomes noticeable a few months after the trigger. The shedding is commonly diffuse rather than a single bare patch.

A dermatologist can distinguish this from pattern hair loss, scalp inflammation and other causes. Seeing hair in the shower does not establish which diagnosis applies.

Weight loss is one possible contributor

Weight loss is a recognized trigger for telogen effluvium, but a relationship between weight change and shedding does not prove that the medicine has no independent effect. Comparing percentages across different drug trials cannot isolate weight-loss speed, nutritional status or pre-existing hair conditions.

The earlier version of this article treated weight loss as the definitive sole cause and predicted the highest hair-loss risk with retatrutide. The available evidence does not support that conclusion.

Hair Loss Rates Across Weight Loss Drugs

Why these rates cannot rank drugs

Approved labels confirm that hair loss occurred more often in these active-treatment groups than with placebo. They do not establish a simple ranking between medicines. Formulation, dose, population and reporting method matter; these figures are not interchangeable with higher-dose Wegovy studies or real-world dermatology cohorts.

What the Research Shows

FAERS pharmacovigilance data (Godfrey et al., JEADV 2025)

Godfrey and colleagues identified disproportionate reporting of alopecia with semaglutide and tirzepatide. A reporting odds ratio is not the percentage of users who lose hair and cannot establish causation. Different reporting patterns also cannot establish that one medicine is safer for hair.

Real-world dermatology data (Burke et al., JAAD 2025)

A retrospective dermatology cohort described several types of hair loss among GLP-1 users, rather than one uniform syndrome. People attending a dermatology clinic are a selected population, so their experience is not a general incidence estimate for everyone starting treatment.

TriNetX cohort study (Vidal et al., JAAD International 2026)

Vidal and colleagues reported associations between GLP-1 use and telogen effluvium, androgenetic alopecia and overall nonscarring hair loss in a matched medical-records cohort. This observational design does not establish whether weight loss, a direct drug effect, residual confounding or several factors explain the association. It does not provide a retatrutide-specific rate.

What About Retatrutide Specifically?

Phase 2 data

The Phase 2 obesity paper did not provide a specific alopecia rate in its main adverse-event table. That is not equivalent to proving that no participant shed hair or that the drug cannot cause it. The study enrolled 338 adults and was not designed to resolve every uncommon dermatologic outcome.

What to expect from Phase 3

Larger safety datasets may help characterize hair loss, but headline Phase 3 releases are not a complete dermatologic analysis. A useful report needs the number of events, treatment and placebo denominators, dose, timepoint and diagnosis. Until then, predicting “at least 4–6%” would be a guess.

The glucagon component — unknown variable

The effect of retatrutide’s glucagon receptor activity on human hair follicles is not established. Other investigational drugs also activate glucagon receptors, so this should not be described as a unique proven hair-risk mechanism.

Prevention and Management Strategies

Management starts with identifying the cause. Temporary shedding after a physical stressor often improves as the trigger settles, but not every case is telogen effluvium and no recovery date can be guaranteed.

Adequate protein intake

Discuss poor intake, rapid weight change and possible deficiencies with the clinician or a dietitian. There is no retatrutide-specific protein or calorie target proven to prevent hair loss. Supplements should address an identified need; taking iron, zinc or biotin without evidence of deficiency is not a reliable treatment and excessive intake can be harmful.

Gradual weight loss

Tell the prescribing clinician if appetite suppression makes it difficult to meet nutritional needs. The treatment plan can be reviewed in that context. A universal calorie floor or slower escalation schedule has not been validated as prevention for retatrutide-associated hair loss.

Medical treatments

Treatments depend on the diagnosis. Minoxidil is used for certain forms of hair loss, but it should not be presented as an approved, proven bridge through every episode of telogen effluvium. A dermatologist can determine whether observation, correction of a trigger or a diagnosis-specific treatment is appropriate.

When to see a dermatologist

Seek assessment for persistent or distressing shedding, patchy loss, scalp symptoms, or worsening pre-existing thinning. You do not have to wait six months if you are worried. A clinician can assess the scalp, review the timing and decide whether tests for an underlying cause are needed.

What We Do Not Know Yet

• A dependable retatrutide-specific rate and the types of hair loss involved.
• Whether direct drug effects contribute independently of weight change or nutrition.
• Comparative risk between medicines in similar patients with similar weight loss.
• The course of symptoms for an individual during continued treatment or after stopping.

Frequently Asked Questions

Sources

• BMJ. (2026). Hair-loss risk in adults with type 2 diabetes: target trial emulation.
• American Academy of Dermatology. Hair shedding versus hair loss and diagnosis and treatment.
• Novo Nordisk/FDA. Current Wegovy label.
• FDA. Current Zepbound label.
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Godfrey, H., et al. (2025). Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology (JEADV). DOI: 10.1111/jdv.20197
• Burke, O., et al. (2025). Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. Journal of the American Academy of Dermatology (JAAD). DOI: 10.1016/j.jaad.2025.01.046
• Vidal, S.I., et al. (2026). Increased Incidence and Risk of Hair Loss with GLP-1 Receptor Agonists: A Real-World Multicenter TriNetX Cohort Study. JAAD International. DOI: 10.1016/j.jdin.2026.01.014
• Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
• Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2206038